Article Text

Download PDFPDF
Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease
  1. Christian Jansen1,
  2. Christopher Bogs1,
  3. Aleksander Krag2,
  4. Sven Francque3,
  5. Jonel Trebicka1,2
  1. 1Department of Internal Medicine I, University of Bonn, Bonn, Germany
  2. 2Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark
  3. 3Department of Gastroenterology and Hepatology, University Hospital Antwerp, Edegem, Belgium
  1. Correspondence to Professor Jonel Trebicka, Department of Internal Medicine I, University of Bonn, Sigmund-Freud Str. 25, Bonn D-53105, Germany; jonel.trebicka{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

With interest we read the letter entitled ‘Ruling in and ruling out with elastography in compensated advanced chronic liver disease’ by Agustin et al1 to our study ‘Algorithm to rule-out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multi-centre study’.2 Indeed, we would like to thank our colleagues for their interest in our study and deciphering the strengths and weaknesses of this study. Besides acknowledging the merits of the study, the colleagues commented on the selection of patients regarding severity and aetiology of advanced chronic liver disease (ACLD), as well as the clinical importance of ruling out or ruling in clinically significant portal hypertension (CSPH).

The criticism about the selection of patients stimulated us to perform new calculations. Even though the algorithm was calculated including patients with decompensated ACLD (dACLD), it performed much better in …

View Full Text


  • Contributors CJ, CB and JT wrote the letter and performed calculation, SF and AK approved and critically discussed the letter.

  • Funding This study was supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18), the H. J. & W. Hector Stiftung, Ernst-Bertha-Grimmke-Stiftung (6/15) and European Union's Horizon 2020 research and innovation programme (No 668031).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval University of Bonn.

  • Provenance and peer review Not commissioned; internally peer reviewed.